Cell secreted minibodies and uses thereof
AssigneesNovartis AG, The Trustees of the University of Pennsylvania
InventorsLaura Alexandra Johnson, Danielle Cook
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.
Claims24
A method of treating a disease or condition in a subject comprising administering a population of modified T cells to a subject in need thereof, wherein:
- (i) the modified T cells express a nucleic acid encoding a minibody, wherein the minibody comprises a single chain antibody comprising a secretion signal, a variable heavy chain fragment, a variable light chain fragment and a constant chain fragment, and a minibody hinge domain between the variable light chain fragment and the constant chain fragment and the modified T cells secrete the minibody, wherein the minibody binds to an immune checkpoint molecule;
- and
- (ii) the modified T cells express a nucleic acid encoding a chimeric antigen receptor (CAR).
Dependencies are inferred from the claim text.